Phase Forward (NASDAQ: PFWD), a leading provider of data management
solutions for clinical trials and drug safety, will participate in the 3rd
annual World
Drug Safety Congress Europe, to be held September 15-18 at the
Bloomsbury Hotel in London, U.K.
On Wednesday, September 16, from 1:30-2:00 p.m. local time, Robert
Weber, principal consultant of Phase Forward’s Lincoln Safety Group,
will participate in stream session 2 titled "Post Marketing Safety
Strategy.” Mr. Weber’s presentation will review the prioritization,
tracking and management of signals from multiple sources, such as
spontaneous adverse event reports, clinical studies and observational
studies. In addition, Mr. Weber will discuss the importance of processes
and integrated tools to deliver improved safety monitoring and risk
management.
Phase Forward will also showcase its safety solutions, the Empirica™
Suite, which comprises the following products: Empirica Trace, Empirica
Gateway, Empirica Signal and Empirica Study.
Members of the media interested in speaking with Mr. Weber and/or Phase
Forward at the event should visit Phase Forward booth #7 or contact
Maria Sumner at +44 1628 640743 or maria.sumner@phaseforward.com.
About Phase Forward
Phase Forward is a leading provider of integrated data management
solutions for clinical trials and drug safety. Phase Forward’s products
and services have been utilized in over 10,000 clinical trials involving
more than 1,000,000 clinical trial study participants at over 290
organizations and regulatory agencies worldwide including: AstraZeneca,
Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S.
Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research
Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International,
Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research
Institute, Servier, SGS, Tibotec and the U.K. Medicines and Healthcare
Products Regulatory Agency. Additional information about Phase Forward
is available at www.phaseforward.com.